NATICK, Mass. — Allurion Technologies said it has treated its first commercial patients in the United States, marking the company’s entry into the country’s obesity treatment market.
The milestone signals the official launch of Allurion’s weight-loss program in the U.S., as the company seeks to position its approach as an alternative to widely used GLP-1 medications.
The company said it is seeing growing interest from patients who have stopped using GLP-1 therapies due to side effects, concerns about long-term use, or weight regain after discontinuing treatment. Early patient demand, it said, reflects interest in non-surgical and non-pharmaceutical options that can deliver faster results.
Initial feedback from clinical centers offering the program has been positive, with providers highlighting the simplicity of the treatment. The procedure takes about 15 minutes and does not require endoscopy or anesthesia, according to the company.
“The feedback we are receiving from our first U.S. customers and partners has been extremely encouraging,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “Centers are reporting that the Allurion Program fills a critical gap in their treatment offerings. Early patient adoption—particularly among those coming off GLP-1s—underscores the real-world need for an effective, fast solution that is safe and sustainable. This level of early validation strongly reinforces our strategic positioning as we enter the U.S. market.”
Allurion also said it is exploring partnerships with self-insured employers as part of a broader strategy to expand access to its Smart Capsule technology through workplace health coverage. The company said such partnerships could help employers manage rising healthcare costs tied to obesity while increasing patient access.
“Our focus now is on thoughtful, disciplined expansion,” Dr. Gaur added. “That includes scaling our provider network, expanding partnerships, and working toward innovative access models—such as self-insured employer coverage—that can meaningfully broaden patient access while delivering value across the healthcare ecosystem.”
The company said it plans to continue building out its network of clinical providers and partnerships as it scales operations in the U.S. market.
